Amarin Corporation PLC (AMRN) Options

Well the good news is that I didn't hit a gas line😩 or water line ......and that I got to dig out the sewer line by hand myself and experienced NO chest pains ..that Vascepa must be working !!

I'm currently prescribed Repatha , Crestor , Zetia and Vascepa ( at max doses ) ...must be a first on this board .
I'm heading to a -ve LDL number :--)

Good luck with the earnings report and these crazy buyout numbers some of U float

Kiwi ...if you need your sewer line cracked during a foundation drilling operation ...I'm your man :--(

Yikes..... you got a love it when you are in the middle of a tough project and you make it worse.....but hey, you can save a lot of money by doing it yourself unless you end up cracking a sewer pipe

Looks like earnings for Q1 is Wednesday May 7th before the open (two days ahead of the AGM on the 9th). Good luck to all…

I'd settle for some RWE ( Real world evidence ) .....how many posters put themselves on ignore . Is that only experienced by long term AMRN posters or seen also on other IHUB boards . Maybe it's a newly discovered side effect of long term posting.
Sorry can't be more creative . I've spent the day digging around a sewer pipe that I cracked while drilling the foundation support for a car turnaround deck .
Spent the day in the dirt ...lucky me
Kiwi

Any reason we are up .28 after hours

Michael

Bull, perfect (and timely!) analogy! 🤣

Amarin is unlike most other companies. No longer a biotech "startup" (ie. not in clinical/research stage), commercialized, but they backslid after losing the patents. Loss of patent in largest market, industry disagreement on their ONLY product (ie. mineral oil debacle, etc.), a series of mis-steps, management/board attacked by activist shareholder, slower-than-expected rollout in Europe (plus resistance from certain countries), loss of NASDAQ listing, and lack of "sense of urgency" by management and board, coupled with no forward guidance.

Basically, a horribly run company with a good product (and a string of bad luck).

They are essentially having to claw their way back from the brink. Unfortunately for us, they have to earn back their market cap. They will. But it's just going to take more time.

They are not going to increase much. There is sales in England and Spain and that is basically it. And England barely moves each quarter. Still no approvals in Fance and Germany so I have no idea where you think this revenue is going to come from. $50 would probably be a gift at this point to end the misery.

Market blackballed AMRN like NFL teams did with Sanders in the draft. Lol

Sanders had his headphones around his neck in the interviews, playing music, among other things he pulled. It reminds me of our former CEO years ago. That's probably how he walked into a meeting with Pfizer. "Yo, you talk 12, come to me with 25, and we can start talking. Peace out!" Hahahahahaha

This is a simple math you just shared with , question is why market has not calculated it ? We are under $10 almost a year or long. Seriously it's a fishy company and stock.

abka, $50 would be throwing in the towel. At 3.5x revenue multiple, that implies roughly $180M in peak annual revenues. So to only hit $50, we would have to assume revenues barely increase from where we are currently.

IMO, the stock should be trading in the $50 range, TODAY.

Ok, Thanks to support they figured it out. For some reason I put myself on IGNORE. Maybe I should keep it that way! lol

Thank you

People talk about 100/150/200 etc price for this stock. I would be really happy it ever reach 50$

Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Published online:28 April 2025
https://www.uscjournal.com/articles/strategies-secondary-prevention-atherosclerotic-cardiovascular-disease?language_content_entity=en

Fantastic NEWS for AMRN

AMRN has been voted as the most likely stock to offer buying opportunities on a consistent basis. I knew they could do it . I also am very certain that Vascepa will prove better than any of these DEVELOPMENTS because we all believe it to be so !! Buying more today and YOU should to !!!

Emerging Therapies (Targeting Lipoprotein(a))

Lepodisiran (Eli Lilly) – siRNA therapy, reduces Lp(a) up to 95%.

Olpasiran (Amgen) – siRNA therapy, reduces Lp(a) up to 97%.

Pelacarsen (Novartis/Ionis) – Antisense therapy, reduces Lp(a) up to 80%.

YS2302018 (CSPC/AstraZeneca) – Small molecule targeting Lp(a), early development.

New Oral PCSK9 Inhibitors and Cholesterol-Lowering Drugs

AZD0780 (AstraZeneca) – Oral PCSK9 inhibitor, LDL-C reduction up to 78%.

Obicetrapib (NewAmsterdam Pharma) – CETP inhibitor, LDL-C reduction by 33%, Lp(a) by 57%.

Lerodalcibep (LIB Therapeutics) – Monthly PCSK9 inhibitor injection, LDL-C reduction by 50%.

Gene and RNA-Based Therapies

VERVE-101 (Verve Therapeutics) – Gene editing therapy (CRISPR base editing) for PCSK9.

VERVE-102 (Verve Therapeutics) – Next-gen gene editing for PCSK9.

Solbinsiran (Eli Lilly) – siRNA therapy targeting ANGPTL3 to lower LDL-C and triglycerides.

Recently Approved

Leqvio (Inclisiran, Novartis) – FDA-approved siRNA, LDL-C reduction ~50%, injected every 6 months.

Tal...The Chinese national health service, which has already given its approval to Vascepa...has a huge problem...which is that CVD afflicts millions of its population (many of whom are smolkers)...They might be willing to pay for for a low cost generic Vascepa.

Thanks Tal.

And do you mean one capsule, or two capsules once a day?

If it's just one capsule a day, that's even better. Pricing could be far better than any generics (I assume).

Jroon
Epadel EM is one-a-day.

Capt, try logging out and clearing your cache. Then log back in. This site can be squirrely sometimes.

Tal, I would expect (hope?) Vascepa 1.0 to go to Authorized Generic status (MARINE indication only) in the U.S., remove branded Vascepa from the market, and launch Vascepa 2.0 for CVD indication only (under a new name).

My guess is that they would price the AG to undercut the generics for the MARINE indication, and Vascepa 2.0 would naturally be less expensive because it would only require half the API (I think it's only 2 pills per day, correct?).

Ziploc,

Generics cannot compete with a SELF-EMULSIFYING ONE-A-DAY LR-Et-EPA COMBO.

Very strange Capt'n...... perhaps we can get Kiwi to conduct a placebo controlled, double blind study to determine why you are having this issue. It may be something V can have a positive effect on.

Capt'n ....if you get banned, many of us would self ban from this board.......

Thanks. For some reason I can't see my own posts or reply's. WEIRD.

This Amarin PR from ACC25 last month:
https://www.amarincorp.com/news-and-media/amarin-highlights-recent-data-presented-acc25-evaluating

Nothing from a peer reviewed pub yet.

I can see this post Capt.

I see this post. 

Hi Capt, can I ask a favor….. do you have any links to the research on the benefits of taking Vascepa and GLP-1 inhibitors? I have my cardio follow up Thursday and want to talk to him about adding it if it makes sense.

Visible to me 😀

Approval of the Lr Et EPA patent in the U.S. would be followed by:

- marketing of this new improved form of EPA in the U.S. and the ROW with NO generic competition
-relegation of Vascepa to a generic status

This would be a new ball game for Amarin or for a BP acquirer of Amarin

hello Friends. Have I been banned? reply if you see this.

https://www.linkedin.com/feed/update/urn:li:activity:7318303280801927168?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7318303280801927168%2C7322523952533164032%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287322523952533164032%2Curn%3Ali%3Aactivity%3A7318303280801927168%29

ORBAPU, You forget to mention that Nissens STRENGHT trial were based on EPA+DHA - basically the Fish Oil you can buy OTC everywhere.

VASCEPA - used in REDUCE-IT tral - is 8 times purified EPA - encapsulated in patented advanced process,

Comparing the two trials is absolute nonsense.
------------------------------------

https://pubmed.ncbi.nlm.nih.gov/33993205/
------------------------------------

But as most of here will recall' - Steve Nissen - simply couldn't accept that his STRNGHT trial were a total failure that were stopped early.

https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it

Sleven, I will say, Amarin was pretty clear a few years ago in stating that they were not pursuing the combo patent, which they had applied for years ago (something  like 2014 if I remember correctly). 
The fact they are still actively pursing patents on the new formulation is encouraging.

MrFred, IIRC the SEC delayed passing required filings for HF when they execute a short sale. This info was published a couple of months ago and has been delayed for another year.

Yes, the SEC has delayed compliance with Rule 13f-2 and Form SHO until February 20262. Originally, institutional investment managers were required to file their first Form SHO by February 14, 2025, but the SEC granted a temporary exemption to allow more time for firms to implement necessary technical updates.

This delay gives investment managers additional time to refine their compliance systems and address operational challenges.

John,

Publications of LR-EtEPA patent applications were made in:

1) U.S. on 05-23-2024 under No.: US20240165066A1.
2) Mexico on 08-06-2024 under No.: MX20244009147A.
3) Australia on 08-15-2024 under No.: AU2023213684A1.
4) Israel on 09-01-2024 under No.: IL314467A.
5) Korea on 09-30-2024 under No.: KR2024014270A.
6) Europe on 12-04-2024 under No.: EP2374613A.
7) Japan on 02-06-2025 under No.: JP2025503961A.

In the US the post-publishing process includes the examiner’s first Office Action, Response & Amendments, subsequent Office Actions (if needed), then Allowance & Grant with a total timeline of 12-18 months - accelerated tracks not included. Also, subsequent Office Actions are very rare.

the company is not talking until the Patent moat is secure..the USPTO started its examination over a year ago….i’m learning there is a Public screen to the details of the examination and there is a Private screen….the Private screen shows all the back and forth between the lawyers and the USPTO examiner……we need access to that private screen…maybe recent move in the stock is as a result of the government employees trading early and often?

Of course they had to toss this in:"Notably, REDUCE-IT reported a 25% reduction in cardiovascular events, whereas STRENGTH showed only a 1% risk reduction, leading to conflicting interpretations regarding whether EPA truly reduced cardiovascular risk. Subsequent cohort studies have suggested that differences in the comparator oils used in these trials may partially explain the disparity in outcomes [https://www.mdpi.com/2227-9059/13/5/1053#B89-biomedicines-13-01053]; however, the overall efficacy of EPA remains uncertain."

John,
https://patentimages.storage.googleapis.com/4c/b6/24/fba02191b26322/US20240165066A1.pdf
That is the US patent application for LR-EtEPA. Does the company intend to market the product? They haven't done anything with the combination patent.
Sleven,

Omega-3 Fatty Acids and Exercise in Obesity Management: Independent and Synergistic Benefits in Metabolism and Knowledge Gaps
Published: 24 April 2025
https://www.mdpi.com/2079-7737/14/5/463

Lysosomal Stress in Cardiovascular Diseases: Therapeutic Potential of Cardiovascular Drugs and Future Directions
Published: 27 April 2025
https://www.mdpi.com/2227-9059/13/5/1053

correct, but it is not the Patent for the new formulation with LR- EtEPA …that’s the Patent that could lead to the return of U.S. market….poster TalShu did the homework awhile back and posted it’s patent application #18/472875…the public file says its ready to be examined february 2024……its 2024/2025 business, not 2023 or earlier…..the patent should be ready to either be denied or accepted….logic says its has not been issued otherwise the company would be obligated to issue an announcement

https://stocktwits.com/SanDiegoLiving/message/612794067

https://stocktwits.com/SanDiegoLiving/message/612785169

Care to comment?

2023-01-06
Priority to US18/151,382
2023-01-10
Application granted
2023-01-10
Publication of US11547710B2
Status
Active
2034-03-14
Anticipated expiration


Seems like your knowledge is not very good. Next time why don't you just search their patents instead of asking for someone to show you evidence. Lol

John,
https://patents.google.com/patent/US20190099422A1/en
This is the US combination patent held by Amarin. It was approved in 2023.
Sleven,

John, I think you ate correct. I'll check. From memory, Patent is issued for a combination product and pending for the self emulsifying product.
https://patentimages.storage.googleapis.com/1c/1c/34/8c7e9f1a69ac21/EP3248599B1.pdf
European combination patent.
Sleven,

Steven……….you’re making news………you state that Amarin holds a patent on new formulation….are you saying that Patent has been approved? to my knowledge, they hold a Patent Application…..would appreciate any evidence that the Patent for new formulation has issued/approved…thanks

Tat, Not sure. I probably use his full name because I have been doing quite a few google searches recently. I think I have had enough of this conversation.
Enjoy your weekend.
Sleven,